"The decision was made at the recommendation of an independent data monitoring committee, which reviewed a futility analysis of a phase 3 trial, Prothena said. In addition, a phase 2b study didn't meet its primary or secondary endpoints. The decision "comes as an early negative surprise," said RBC Capital Markets analyst Kennen MacKay."
Market Data 
Markets 
AI
